UConn Update #2

SARS-CoV-2 and COVID-19

Educational Objectives

After participating in this activity, pharmacists will be able to:

  • List treatments that are currently being investigated for COVID-19
  • Recognize issues of concern related to hydroxychloroquine
  • Describe the science behind ABO blood groupings and human susceptibility to viruses

Session Offered

Release Date: April 13, 2020

Expiration Date: December 31, 2021

Course Fee

$3 for pharmacists

$3 for technicians

Session Codes

20YC42-ABC93 Pharmacist

20YC42-CBA36 Pharmacy Technician

Accreditation Hours

1.0 hours of CE


UConn faculty assembled this homestudy in response to a high demand to reliable education on coronavirus. It answers questions submitted by our learners.

Accreditation Statements

The University of Connecticut School of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Pharmacists and pharmacy technicians are eligible to participate in this application-based activity and will receive up to 0.2 CEU (2 contact hours) for completing the activity, passing the quiz with a grade of 70% or better, and completing an online evaluation. Statements of credit are available via the CPE Monitor on- line system and your participation will be recorded with CPE Monitor within 72 hours of submission


Grant funding: None

Cost: $3 for pharmacists $3 for technicians

Initial Release Date: April 13, 2020
Expiration Date: December 31, 2021

To obtain CPE credit, visit the UConn Online CE Center

Use your NABP E-profile ID and the session code 20YC42-ABC93 for pharmacists or 20YC42-CBA36 for pharmacy technicians to access the online quiz and evaluation.

First- time users must pre-register in the Online CE Center. Test results will be displayed immediately and your participation will be recorded with CPE Mon- itor within 72 hours of completing the requirements.

For questions concerning the online CPE activities, email joanne.nault@uconn.edu


Cassandra Doyno, Pharm.D., BCPS is an Assistant Clinical Professor,Pharmacy Practice, UConn School of Pharmacy, Storrs, CT.

Jeannette Y. Wick, R.Ph, MBA, FASCP, is the Assistant Director, Office of Pharmacy Professional Development, UConn School of Pharmacy, Storrs, CT.

C. Michael White, Pharm.D., FCP, FCCP; Professor and Chair, Pharmacy Practice, UConn School of Pharmacy, Storrs, CT and Director, HOPES Collaborative Group, University of Connecticut and Hartford Hospital, Hartford, CT.

Jeffrey R. Aeschlimann, Pharm.D. Is an Associate Professor, UConn School of Pharmacy, Adjunct Associate Professor, UConn School of Medicine, UConn Health, Division of Infectious Diseases.

Faculty Disclosure

All faculty have no actual or potential conflicts of interest associated with this article.

Disclosure of Discussions of Off-label and Investigational Drug Use

This activity may contain discussion of off label/unapproved use of drugs. The content and views presented in this educational program are those of the faculty and do not necessarily represent those of the University of Connecticut School of Pharmacy. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.



This is UConn School of Pharmacy’s second update to information related to SARS-CoV-2 viral infection and COVID-19. In previous continuing education (CE) activities, we discussed the virus (SARS-CoV-2), the disease it causes (COVID-19), and frequently asked questions. As time passes and we advance into what we hope will be the peak of the pandemic, new questions arise. As we noted in previous CEs, the situation changes daily (and sometimes hourly), and misinformation is rampant.


Full List of References

1. Alhazzani W, Møller MH, Arabi YM, et al. Surviving sepsis campaign: Guidelines on the management of critically ill adults with coronavirus disease 2019 (COVID-19). Crit Care Med. 2020 Mar 27. doi: 10.1097/CCM.0000000000004363. [Epub ahead of print]

2. Wilson K, et al. COVID-19: Interim Guidance on Management Pending Empirical Evidence. From an American Thoracic Society-led International Task Force. Available at https://www.thoracic.org/professionals/clinical-resources/diseaserelated-resources/covid-19-guidance.pdf. Accessed April 3, 2020.

3. Li G, Clercq ED. Therapeutic options for the 2019 novel coronavirus (2019-nCoV). Nat Rev Drug Discov. 2020;19(3):149-150.

4. Paragas J, Blatt LM, Hartmann C, Huggins JW, Endy TP. Interferon alfacon1 is an inhibitor of SARS-coronavirus in cell-based models. Antiviral Res. 2005;66(2–3):99-102.

5. Wang W, Ye L, Ye L, et al. Up-regulation of IL-6 and TNF-alpha induced by SARS-coronavirus spike protein in murine macrophages via NF-kappaB pathway. Virus Res. 2007;128(1–2):1-8.

6. Barlow A, Landolf KM, Barlow B, et al. Review of emerging pharmacotherapy for the treatment of coronavirus disease 2019. Pharmacotherapy. 2020 Apr 7. doi: 10.1002/phar.2398. [Epub ahead of print]

7. U.S. Food and Drug Administration. Emergency use authorization of hydroxychloroquine sulfate supplied from strategic national stockpile for treatment of covid-19 in certain hospitalized patients. Available at https://www.fda.gov/media/136535/download. Accessed April 3, 2020.

8 Yao X, Ye F, Zhang M et al. In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Clin Infect Dis. 2020; In Press. (PubMed 32150618) doi 10.1093/cid/ciaa237

9. Chen J, Liu D, Li L, et al. A pilot study of hydroxychloroquine in treatment of patients with common coronavirus disease-19 (COVID-192020; Mar. (DOI 10.3785/j.issn. Available at https://covid19- evidence.paho.org/handle/20.500.12663/806. Accessed April 10. 2020.

10. U.S. Centers for Disease Control and Prevention. Coronavirus Disease 2019 (COVID-19): Information for clinicians on therapeutic options for COVID-19 Patients. Avaialble at https://www.cdc.gov/coronavirus/2019-ncov/hcp/therapeuticoptions.html. Accessed Mar 26, 2020.

11. Cortegiani A, Ingoglia G, Ippolito M, Giarratano A, Einav S. A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19. J Crit Care. 2020 Mar 10. pii: S0883-9441(20)30390-7. doi: 10.1016/j.jcrc.2020.03.005. [Epub ahead of print]

12. Gautret P, Lagier JC, Parola P, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label nonrandomized clinical trial. Int J Antimicrob Agents. 2020 Mar 20:105949. doi: 10.1016/j.ijantimicag.2020.105949. [Epub ahead of print]

13. Gautret P, Lagier JC, Parola P, et al. Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: an observational study. Preprint. Avaiable at https://www.mediterraneeinfection.com/wp-content/uploads/2020/03/COVID-IHU-2-1.pdf. Accessed April 9, 2020.

14. Best BM, Capparelli EV, Diep H, et al. Pharmacokinetics of lopinavir/ritonavir crushed versus whole tablets in children. J Acquir Immune Defic Syndr. 2011;58(4):385-391.

15. Genetech Medical Communications. Actemra Prefilled Syringe for Intravenous Infusion. Genetech, Inc. 1 April 2020.

16. U.S. Food and Drug Administration. Recommendations for investigational COVID-19 convalescent plasma. Avaialble at https://www.fda.gov/vaccines-blood-biologics/investigational-newdrug-ind-or-device-exemption-ide-process-cber/recommendationsinvestigational-covid-19-convalescent-plasma#Patient%20Eligibility. Accessed April 10, 2020.

17. Plaquenil (hydroxychloroquine) package insert. St. Michael, Barbados: Concordia Pharmaceuticals, Inc.; January 2017.

18. Zithromax (azithromycin 250 mg and 500 mg tablets and azithromycin oral suspension) package insert. New York, NY: Pfizer Inc.; April 2019.

19. Actemra (tocilizumab) injection package insert. South San Francisco, CA: Genentech, Inc.; June 2019.

20. Kaletra (lopinavir; ritonavir) tablet and solution package insert. North Chicago, IL: AbbVie Inc; December 2019.

21. World Health Organization. Clinical management of severe acute respiratory infections (SARI) when COVID-19 disease is suspected. Available at https://www.who.int/publications-detail/clinicalmanagement-of-severe-acute-respiratory-infection-when-novelcoronavirus-(ncov)-infection-is-suspected. Accessed April 11, 2020.

22. Smith T, Bushek J, LeClaire A, Prosser T. COVID-19 Drug Therapy. Available at https://www.elsevier.com/__data/assets/pdf_file/0007/988648/COVID -19-Drug-Therapy_Mar-2020.pdf. Accessed April 11, 2020.

23. Liverpool Drug Interactions Group. Experimental COVID-19 therapies: Administration in cases of swallowing difficulties. Available at https://liverpool-covid19.s3.eu-west-2.amazonaws.com/landingpage/Covid__Swallowing_2020_Mar13.pdf. Accessed April 11, 2020.

24. Farkas J. Internet Book of Critical Care. COVID-19. Available at https://emcrit.org/ibcc/covid19/. Accessed April 11, 2020.

25. Pesko LJ. Hydroxychloroquine Oral suspension compounding: hydroxychloroquine. Am Drug. 1993;207(4):57:

26. U.S. Food and Drug Administration. Fact sheet for health care providers emergency use authorization (EUA) of hydroxychloroquine sulfate supplied from the strategic national stockpile for treatment of COVID-19 in certain hospitalized patients. Available at https://www.fda.gov/media/136537/download. Accessed April 9, 2020.

27. Arkansas Department of Health. Choroquine and hydroxychloroquine information. March 21, 2020. Available at https://www.healthy.arkansas.gov/images/uploads/pdf/hydroxychloro quine_document_(final_on_letterhead).pdf. Accessed April 9, 2020.

28. State of Ohio Board of Pharmacy. Emergency rule for dispensing chloroquine and hydroxychloroquine – Effective 3/22/2020. Available at https://www.pharmacy.ohio.gov/Documents/Pubs/Newsletter/2020/E mergency%20Rule%20for%20Dispensing%20Chloroquine%20and%20H ydroxychloroquine%20Effective%203.22.2020.pdf. Accessed April 9, 2020.

29. The Nobel Prize. Karl Landsteiner. Available at https://www.nobelprize.org/prizes/medicine/1930/landsteiner/biogra phical/. Accessed April 9, 2020.

30. Dean L. Blood groups and red cell antigens. Chapter 5: The ABP blood group. Available at https://www.ncbi.nlm.nih.gov/books/NBK2267/. Accessed April 10, 2020.

31. Alpoim PN, de Barros Pinheiro M, Junqueira DRG, et al. Preeclampsia and ABO blood groups: a systematic review and meta-analysis. Mol Biol Rep. 2013;40:2253-2261.

32. He M, Wolpin B, Rexrode K, et al. ABO blood group and risk of coronary heart disease in two prospective cohort studies. Arterioscler Thromb Vasc Biol. 2012;32(9):2314-2320.

33. Wang W, Liu L, Wang Z, et al. ABO blood group and esophageal carcinoma risk: from a case-control study in Chinese population to metaanalysis. Cancer Causes Control. 2014;25:1369-1377.

34. Miao SY, Zhou W, Chen L, Wang S, Liu XA. Influence of ABO blood group and Rhesus factor on breast cancer risk: a meta-analysis of 9665 breast cancer patients and 244,768 controls. Asia Pac J Clin Oncol. 2014;10(2):101-108.

35. Socha WW. Blood groups of apes and monkeys: current status and practical applications. Lab Anim Sci. 1980 Aug;30(4 Pt 1):698-702.

36. Choate JD. ABO and Rh blood groups. Clinical Principles of Transfusion Medicine. Maitta RW, ed. 2018.

37. Zhao J, Yang Y, Huang H, et al. Relationship between the ABO blood group and the COVID-19 susceptibility. MedRciv. Available at https://www.medrxiv.org/content/10.1101/2020.03.11.20031096v2.fu ll.pdf. Access April 9, 2020. Preview.

38. Cooling L. Blood groups in infection and host susceptibility. Clin Microbiol Rev. 2015 Jul;28(3):801-870. doi: 10.1128/CMR.00109-14.

39. Johnson PC, Mathewson JJ, DuPont HL et al. Multiple challenge study of host susceptibility to Norwalk gastroenteritis in US adults. J Infect Dis. 1990;161:18-21.

40. Donaldson EF, Lindesmith LC, Lobue AD et al. Viral shapeshifting: norovirus evasion of the human immune system. Nat Rev Microbiol. 2010;8:231-241.

41. Marionneau S, Ruvoën N, Le Moullac-Vaidye B, et al. Norwalk virus binds to histo-blood group antigens present on gastroduodenal epithelial cells of secretor individuals. Gastroenterology. 2002;122:1967- 1977.

42. Liao Y, Xue L, Gao J, Wu A, Kou X. ABO blood group-associated susceptibility to norovirus infection: A systematic review and meta-analysis. Infect Genet Evol. 2020 Feb 21;81:104245. doi: 10.1016/j.meegid.2020.104245. [Epub ahead of print]

43. Batool Z, Durrani SH, Tariq S. Association of ABO and Rh blood group types to hepatitis B, hepatitis C, HIV and syphilis infection, a five year experience in healthy blood donors in a tertiary care hospital. J Ayub Med Coll Abbottabad. 2017;29(1):90-92.

44. Jing W, Zhao S, Liu J, Liu M. ABO blood groups and hepatitis B virus infection: a systematic review and meta-analysis. BMJ Open. 2020;10(1):e034114.

45. Liu J, Zhang S, Liu M, et al. Distribution of ABO/Rh blood groups and their association with hepatitis B virus infection in 3.8 million Chinese adults: A population-based cross-sectional study. J Viral Hepat. 2018;25(4):401-411.

46. Casadevall A, Dadachova E, Pirofski LA. Passive antibody therapy for infectious diseases. Nat Rev Microbiol. 2004;2(9):695-703.

47. Graham BS, Ambrosino DM. History of passive antibody administration for prevention and treatment of infectious diseases. Curr Opin HIV AIDS. 2015;10(3):129-134.